- Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
- The company recently announced the rollout of its Miboko application by targeting insurers and employers
- In 2019, over $760 billion was spent on diabetes-related health care, equating to $9,000 per diabetic patient compared to $1,600 for a non-diabetic individual
- The Miboko application provides users with an efficient and accurate means of tracking their day-to-day glycaemic levels, a key determinant of overall metabolic health
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced that it would launch Miboko, the company’s new metabolic health program using a non-invasive glucose sensor, for the use of employers and insurers worldwide. Nemaura Medical aims to promote the broad penetration and adoption of the Miboko device as a form of preventative medicine for a broad user base. The company opts to pursue the above commercial distribution channels to ensure the device’s successful rollout and adoption (https://ibn.fm/Yd5xE).
Over 420 million people globally are currently living with diabetes, with prediabetic cases totalling almost three times that number. Meanwhile, and in the US alone, over…
NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.